| 1 Swerdlow SH,Campo E,Pileri SA,et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J].Blood,2016,127(20):2375-2390.
2 Salzmann S,Lang I,Rosenthal A,et al.TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes[J].J Immunol,2013,191(5):2308-2318.
3 Ushmorov A,Leithuser F,Sakk O,et al.Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma[J].Blood,2006,107(6):2493-2500.
4 Chik F,Szyf M,Rabbani SA.Role of epigenetics in cancer initiation and progression[J].Adv Exp Med Biol,2011,7(20):91-104.
5 Ammerpohl O,Haake A,Pellissery S,et al.Array-based DNA methylation analysis in classical Hodgkin lymphoma reveals new insights into the mechanisms underlying silencing of B cell-specific genes[J].Leukemia,2012,26(4):185-188.
6 Cowan LA,Talwar S,Yang AS.Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors[J].Epigenomics,2010,2(1):71-86.
7 Glozak MA,Sengupta N,Zhang X,et al.Acetylation and deacetylation of non-histone proteins[J].Gene,2005,36(3):15-23.
8 Marmorstein R.Structure and function of histone acetyltransferases[J].Cell Mol Life Sci,2001,58(56):693-703.
9 Morin RD,Mendez-Lago M,Mungall AJ,et al.Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma[J].Nature,2011,476(7360):298-303.
10 Haery L,Thompson RC,Gilmore TD.Histone acetyltransferases and histone deacetylases in B-and T-cell development,physiology and malignancy[J].Genes Cancer,2015,6(6):184-213.
11 Eliseeva ED,Valkov V,Jung M,et al.Characterization of novel inhibitors of histone acetyltransferases[J].Mol Cancer Ther,2007,6(9):2391-2398.
12 Adams H,Fritzsche FR,Dirnhofer S,et al.Class I histone deacetylases 1,2 and 3 are highly expressed in classical Hodgkin's lymphoma[J].Expert Opin Ther Targets,2010,14(6):577-584.
13 West AC,Johnstone RW.New and emerging HDAC inhibitors for cancer treatment[J].J Clin Invest,2014,124(1):30-39.
14 Younes A,Sureda A,Ben-Yehuda D,et al.Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation:results of a phase II study[J].J Clin Oncol,2012,30(18):2197-2203.
15 Younes A,Oki Y,Bociek RG,et al.Mocetinostat for relapsed classical Hodgkin's lymphoma:an open-label,single-arm,phase 2 trial[J].Lancet Oncol,2011,12(13):1222-1228.
16 Gubin MM,Zhang X,Schuster H,et al.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J].Nature,2014,515(7528):577-581.
17 Vardhana S,Younes A.The immune microenvironment in Hodgkin lymphoma:T cells,B cells,and immune checkpoints[J].Haematologica,2016,101(7):794-802.
18 Steidl C,Shah SP,Woolcock BW,et al.MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers[J].Nature,2011,471(7338):377-381.
19 Mehta NT,Truax AD,Boyd NH,et al.Early epigenetic events regulate the adaptive immune response gene CIITA[J].Epigenetics,2011,6(4):516-525.
20 Green MR,Monti S,Rodig SJ,et al.Integrative analysis reveals selective 9p24.1 amplification,increased PD-1 ligand expression,and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma[J].Blood,2010,116(17):3268-3277.
21 Yang H,Bueso-Ramos C,DiNardo C,et al.Expression of PD-L1,PD-L2,PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents[J].Leukemia,2014,28(6):1280-1288.
22 Green MR,Rodig S,Juszczynski P,et al.Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders:implications for targeted therapy[J].Clin Cancer Res,2012,18(6):1611-1618.
23 Li B,Greene MI.FOXP3 actively represses transcription by recruiting the HAT/HDAC complex[J].Cell Cycle,2007,6(12):1432-1436.
24 Ansell SM,Lesokhin AM,Borrello I,et al.PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma[J].N Engl J Med,2015,372(4):311-319.
25 Villasboas JC,Ansell S.Checkpoint inhibition:programmed cell death 1 and programmed cell death 1 ligand inhibitors in hodgkin lymphoma[J].Cancer J,2016,22(1):17-22.
26 Khot A,Dickinson M,Prince HM.Panobinostat in lymphoid and myeloid malignancies[J].Expert Opin Investig Drugs,2013,22(9):1211-1223.
27 Oki Y,Buglio D,Zhang J,et al.Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression[J].Blood Cancer J,2014,4(4):23-26.
28 West AC,Smyth MJ,Johnstone RW.The anticancer effects of HDAC inhibitors require the immune system[J].Oncoimmunology,2014,3(1):27-34.
29 Beg AA,Gray JE.HDAC inhibitors with PD-1 blockade:a promising strategy for treatment of multiple cancer types[J].Epigenomics,2016,8(8):1015-1017.
30 Zheng H,Zhao W,Yan C,et al.HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma[J].Clin Cancer Res,2016,22(16):4119-4132.
31 Woods DM,Sodre AL,Villagra A,et al.HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade[J].Cancer Immunol Res,2015,3(12):1375-1385. |
